4 completed, 2 recruiting, 1 not yet recruiting. 7 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Recruiting 2, Not yet recruiting 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
| Phase 1 | 1 | Completed 1 |
Follow Lymphangioma: new trials by email Literature Review of Lymphangioma trials Research Report on Lymphangioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies Everolimus - Vascular Malformations, Arteriovenous Malformations | Phase 2 | Not yet recruiting | Yonsei University | 67 | 2026-04-01 | 2026-03-17 |
| A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations Alpelisib, Mirdametinib - Slow-Flow Vascular Malformation, Fast-Flow Vascular Malformation | Phase 2 | Recruiting | Murdoch Childrens Research Institute | 50 | 2024-09-13 | 2026-05-05 |
| Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. Alpelisib, Placebo - Lymphatic Malformations | Phase 2 / Phase 3 | Recruiting | Novartis Pharmaceuticals | 232 | 2023-11-24 | 2026-10-09 |
| Study Evaluating the Safety and Efficacy of PTX-022 (QTORIN Sirolimus) in the Treatment of Microcystic Lymphatic Malformations PTX-022 - Microcystic Lymphatic Malformation | Phase 2 | Completed | Palvella Therapeutics, Inc. | 12 | 2022-01-13 | 2025-01-17 |
| A Study to Evaluate Sildenafil for the Treatment of Lymphatic Malformations Sildenafil - Lymphangioma | Phase 1 / Phase 2 | Completed | Stanford University | 7 | 2010-12-01 | 2015-06-19 |
| Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies sirolimus - Kaposiform Hemangioendotheliomas, Tufted Angioma | Phase 2 | Completed | Denise Martin Adams | 61 | 2009-10-01 | 2026-01-06 |
| Study of Picibanil (OK432) Sclerotherapy in Children With Macrocystic Lymphatic Malformations picibanil - Lymphatic Malformations | Phase 2 / Phase 3 | Completed | University of Iowa | 150 | 2000-04-01 | 2015-03-25 |
Lymphatic Abnormalities (4) · Lymphangioma, Cystic (3) · Vascular Malformations (3) · Arteriovenous Malformations (2) · Hemangioendothelioma (1) · Hemangioma (1) · Nevus (1) · Skin Diseases, Vascular (1) · Thrombocytopenia (1) · Tufted angioma (1)
Neoplasm, Lymphatic Tissue (7) · Neoplasms (7) · Neoplasms by Histologic Type (7) · Congenital Abnormalities (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Hemic and Lymphatic Diseases (5) · Lymphatic Diseases (4) · Cardiovascular Abnormalities (3) · Cardiovascular Diseases (3) · Vascular Diseases (2) · Blood Platelet Disorders (1) · Cytopenia (1) · Hematologic Diseases (1) · Neoplasms, Vascular Tissue (1) · Nevi and Melanomas (1)
Alpelisib (2) · Everolimus (1) · Picibanil (1) · Sildenafil Citrate (1) · Sirolimus (1) · mirdametinib (1)
Denise Martin Adams (1) · Murdoch Childrens Research Institute (1) · Novartis Pharmaceuticals (1) · Palvella Therapeutics, Inc. (1) · Stanford University (1) · University of Iowa (1) · Yonsei University (1)
United States (5) · Australia (2) · Argentina (1) · Belgium (1) · Czechia (1) · France (1) · Germany (1) · Italy (1) · Netherlands (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Alfred T Lane, MD (1) · Denise M Adams, MD (1) · Lydia Pathmanathan, MBBS, FRACP. (1) · Richard J Smith (1) · Stephen Luen, MBChB, FRACP. (1) · Tony Penington, MBBS, FRACS. (1)
PMID 19117316, PMID 24656411, PMID 30672136, PMID 35852876
2023 (1), UL1TR000093 (1)